Voyager Therapeutics (NASDAQ:VYGR) Issues Earnings Results, Beats Expectations By $0.06 EPS

Voyager Therapeutics (NASDAQ:VYGR) reported earnings of ($0.47) per share, exceeding expectations of ($0.53) by $0.06. The company has a negative return on equity of 37.65% and a negative net margin of 253.49%. Following the earnings report, Voyager's stock rose 30% to $4.26. Institutional investors hold 48.03% of the stock, with recent modifications in holdings by major firms. Analysts have mixed ratings, with an average target price of $12.96, indicating a "Moderate Buy" sentiment.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.06, Zacks reports. Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%.

Get Voyager Therapeutics alerts:

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock pops 30% on deal with Novartis

NASDAQ VYGR traded up $0.03 during mid-day trading on Monday, reaching $4.26. 556,597 shares of the stock were exchanged, compared to its average volume of 573,133. The business's fifty day simple moving average is $4.51 and its 200 day simple moving average is $3.71. Voyager Therapeutics has a 1-year low of $2.64 and a 1-year high of $7.44. The stock has a market capitalization of $236.30 million, a PE ratio of -2.30 and a beta of 0.95.

Insider Buying and Selling

In related news, CFO Nathan D. Jorgensen sold 7,666 shares of the business's stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $4.78, for a total transaction of $36,643.48. Following the transaction, the chief financial officer directly owned 123,834 shares of the company's stock, valued at approximately $591,926.52. The trade was a 5.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 4.53% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its position in Voyager Therapeutics by 1.3% during the third quarter. Vanguard Group Inc. now owns 3,250,066 shares of the company's stock worth $15,178,000 after purchasing an additional 40,147 shares during the period. Geode Capital Management LLC increased its position in shares of Voyager Therapeutics by 1.1% during the second quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company's stock valued at $3,474,000 after acquiring an additional 11,929 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Voyager Therapeutics by 179.3% in the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company's stock worth $1,674,000 after buying an additional 317,927 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of Voyager Therapeutics by 863.3% in the 1st quarter. Acadian Asset Management LLC now owns 230,708 shares of the company's stock worth $778,000 after purchasing an additional 206,758 shares during the period. Finally, Hsbc Holdings PLC increased its holdings in Voyager Therapeutics by 118.5% in the 2nd quarter. Hsbc Holdings PLC now owns 148,377 shares of the company's stock worth $440,000 after acquiring an additional 80,474 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

VYGR has been the topic of several recent research reports. Wedbush lowered their price target on shares of Voyager Therapeutics from $9.00 to $8.00 and set an "outperform" rating on the stock in a research report on Thursday, August 7th. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of Voyager Therapeutics in a report on Monday, September 15th. Finally, Weiss Ratings restated a "sell (d)" rating on shares of Voyager Therapeutics in a research note on Wednesday, October 8th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $12.96.

Read Our Latest Analysis on VYGR

Voyager Therapeutics Company Profile

(Get Free Report)

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.

Should You Invest $1,000 in Voyager Therapeutics Right Now?

Before you consider Voyager Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.

While Voyager Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here